| Project/Area Number |
16K19943
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kumamoto University (2017-2018)
Japanese Foundation for Cancer Research (2016) |
|---|
Principal Investigator |
TOKUNAGA Ryuma 熊本大学, 医学部附属病院, 非常勤診療医師 (20594881)
|
|---|
| Research Collaborator |
BABA Hideo
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 大腸癌 / マイクロRNA / 細胞周期 / 血管新生 / 上皮間葉転換 / 化学療法 / JMJD3 / エピジェネティクス / EZH2 |
|---|
| Outline of Final Research Achievements |
We showed for the first time that JMJD3 low expression in colorectal cancer was a poor prognostic factor and that JMJD3 regulated p15INK4b to suppress tumor progression. In addition, miR186-5p was identified as a microRNA which suppressed JMJD3 from the result of a microRNA array. Furthermore, we found that miR186-5p suppressed apoptosis, promoted cell cycle, and increased proliferation in colorectal cancer cell, and confirmed that the expression levels of miR186-5p and JMJD3 are inversely correlated in clinical samples. However, no significant correlation was detected between the expression level of miR186-5p and the patient prognosis or tumor progression status.
|
| Academic Significance and Societal Importance of the Research Achievements |
大腸癌は本邦における癌罹患数および臓器別癌死亡数で上位を占め、世界的に研究がすすめられている癌腫である。我々は大腸癌におけるエピジェネティクスを標的とした新規分子標的治療薬を開発することを目標として本研究を行った。今まで大腸癌におけるJumonji-domain containing 3 (JMJD3)の役割については報告がなく、今回の研究においてmiR186-5pがJMJD3を制御すること、および癌の進展に関わっていることを初めて示すことができた。これはmiR186-5pやJMJD3をターゲットとした新規治療薬の開発につながる可能性がある。
|
